Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
January 09, 2025 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug...
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024 07:00 ET
|
Acumen Pharmaceuticals, Inc.
Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline...
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 11, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
November 06, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
November 06, 2024 08:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024
November 05, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
October 31, 2024 08:05 ET
|
Acumen Pharmaceuticals, Inc.
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture...
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 23, 2024 08:00 ET
|
Acumen Pharmaceuticals, Inc.
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer’s disease - Late-breaking presentation to be...
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
September 30, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...